Delavirdin
DefinitionThis section has been translated automatically.
Virustatic. Non-nucleoside inhibitor of the reverse transcriptase of HIV.
IndicationThis section has been translated automatically.
Antiretroviral combination therapy for the treatment of HIV-1 infection.
Dosage and method of useThis section has been translated automatically.
3 times/day 400 mg p.o.
Undesirable effectsThis section has been translated automatically.
Cutaneous NW (approx. 50% of patients, usually 2nd-4th week of therapy, truncated or on the upper extremity) such as erythema, erythema exsudativum multiforme, urticaria. Gastrointestinal symptoms such as nausea, headaches, dizziness.
ContraindicationThis section has been translated automatically.
Patient with severe liver and kidney dysfunction (e.g. WHO group III-IV), children < 3 years. Comedication with rifampicin, phenobarbital, phenytoin or CYP3A4 substrates such as terfenadine, St. John's wort, cisapride, pimozide, antidepressants (e.g. diazepam, midazolam, flurazepam) ergotamine derivatives, astemizole, etc.
PreparationsThis section has been translated automatically.
Rescriptor (available through the international pharmacy)
Note(s)This section has been translated automatically.
Remember! 100% cross-resistance with nevirapine!